Looking at the yahoo stock chart - what I see is that 178K traded at $2.61 not $2.92 - the $2.92 was a trade at the very end of day for 1K share and it may have been someone who in error keyed in $2.92 rather than $2.62
Don't agree with that at all - I don't think percentage has anything at all to do with market potential - It all has to do with how far along the path to approval the drug is - preclinical gets you 5% to 8 % - successful phase 1 about 10% to 15% - phase 2 , about 15 to 25 % phase 3 = 25 to 35% - FDA approved = 35 to 50% and usually the lower the percentage the bigger the milestone payments. - IPCI would be handing over a ready for market drug with 180 days exclusivity... if they don't get 50% they should get a very hefty up front payment.
When Will the Generic Be Available?: Some or all forms of Seroquel XR may become available as generic quetiapine xr after November 2016, depending on FDA approval and patent expiration.
I believe IPCI was first to file and has 180 day exclusivity on all 5 strenghts, and I believe this is the drug that they have partnered with TEVA.
p.s. Seroquel XR is a $1.2 BILLION drug - 6 months exclusivity = $600 Million x 60% (40% discount over brand name) = $360 million x 25% market capture during 6 month exclusivity = $90 million x 50% (50/50 split with Teva - most likely) = $45 million divided by 25 million shares = $1.80 earnings per share for 6 months x 20 p/e (reasonable for growing concern) = $36.00 +/- 20% = ~ $28.80 to $43.20 fair value per share... just on Seroquel XR.